GCC IgA Nephropathy Disease Landscape

IgA nephropathy (IgAN) is estimated to affect 8,000–12,000 patients across the GCC, but the true IgAN fraction of incident CKD is difficult to establish: most proteinuric patients in the region are attributed to diabetic nephropathy, reflecting the GCC's 20–25% adult diabetes prevalence, without a confirmatory kidney biopsy. KDIGO guidance calls for biopsy in non-diabetic proteinuria, yet a GCC nephrology network capacity survey finds GCC nephrology practice performing biopsy in fewer than 30% of eligible proteinuric patients — versus roughly 70% in Japan and Germany. Under-biopsy is functionally equivalent to under-diagnosis: a patient never biopsied cannot be coded as IgAN, regardless of the underlying pathology.

Once diagnosed, GCC IgAN patients progress to end-stage renal disease 15–20% faster than European observational cohorts, a pattern consistent with later diagnosis (more advanced disease at confirmation), poorly controlled hypertension (mean systolic blood pressure at IgAN diagnosis: 148mmHg versus a sub-130mmHg target), and late initiation of ACE inhibitor or ARB therapy. Kidney biopsy capability itself is concentrated at fewer than 20 GCC centres with dedicated nephrology and interventional radiology teams; the patient journey from proteinuria detection through nephrology referral to biopsy typically adds 3–6 months per step, for a total of 12–24 months from proteinuria detection to IgAN diagnosis, roughly double the 6–12 month benchmark in Europe. GCC patients reaching ESRD represent a meaningful share of the region's 5,000-plus annual dialysis population, with IgAN contributing an estimated 12–15%.

This assessment is built from the IDF Diabetes Atlas, the Gulf renal registry, KDIGO 2021 IgAN guideline benchmarks, and a GCC nephrology network capacity survey, triangulated to separate estimated IgAN prevalence from diabetes-attribution bias in routine proteinuric CKD coding.

Formulary and access status is confirmed against SFDA registration and GCC formulary listings rather than US/EU payer language, reflecting the region's government-hospital-centred nephrology referral model.